Cost-effectiveness of 3-Hydroxy-3-Methylglutaryl–Coenzyme A Reductase Inhibitors in the Secondary Prevention of Cardiovascular Disease

Abstract

These long-term cost estimates are consistent with the short-term economic analyses of the published 4S results. The long-term treatment of hyperlipidemia in secondary prevention is forecasted to be cost-effective across a broad range of patients between 40 and 70 years of age. Recognizing the additional effects of lipid changes on cerebrovascular events can substantially improve the cost-effectiveness of treating hyperlipidemia.